AZD2936 clinical trials

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

This study looks at a new drug, AZD2936, for advanced head and neck cancer, specifically in patients who still have signs of cancer in their blood after their initial treatment. It aims to see if the drug can help clear these signs and improve how well patients do.